Amgen Positions MariTide as Potential ‘Best Monthly’ Obesity Drug

Why It Matters

A monthly obesity drug could capture patients dissatisfied with weekly injections, giving Amgen a competitive edge against Eli Lilly and Novo Nordisk and diversifying its revenue streams.

Key Takeaways

• Phase 3 MARITIME‑Switch studies assess monthly dosing switch from weekly GLP‑1
• Bispecific antibody‑peptide activates GLP‑1 and blocks GIP for sustained weight loss
• MariTide aims to be best monthly or less frequent obesity therapy
• Amgen expects MariTide to expand portfolio beyond obesity into diabetes, heart failure
• First‑quarter revenue rose 6% to $8.6 billion, supporting blockbuster pipeline

Pulse Analysis

The obesity market has become a battleground for big‑pharma, with Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide dominating weekly injection regimens. Patients and providers are increasingly seeking convenience, prompting a shift toward longer‑acting formulations. Amgen’s MariTide, a bispecific antibody‑peptide that simultaneously stimulates GLP‑1 receptors while antagonizing GIP, directly addresses this demand by offering a monthly injection schedule. If the upcoming Phase 3 switch study confirms comparable efficacy and tolerability, MariTide could carve out a niche for patients who struggle with the 52‑injection‑per‑year cadence of current therapies.

Beyond dosing frequency, MariTide’s mechanism promises a dual metabolic effect: enhanced appetite suppression from GLP‑1 activation and improved insulin sensitivity via GIP disruption. Early Phase 2 data indicated up to 20% body‑weight reduction after a year, a figure modest relative to competitors but notable for a monthly agent. The company’s three‑step dose escalation appears to improve tolerability, a critical factor in chronic obesity treatment adherence. Moreover, Amgen is leveraging the molecule’s platform potential, advancing it in type 2 diabetes, heart failure and obstructive sleep apnea, which could broaden its commercial footprint and mitigate the risk of a single‑indication product.

Financially, Amgen’s Q1 earnings showed a 6% YoY revenue increase to $8.6 billion, driven by strong sales of Repatha, Evenity and Prolia. Adding a successful obesity drug could push the company’s annual blockbuster count toward 17, reinforcing its position among the top biotech earners. A monthly obesity therapy would not only diversify Amgen’s revenue base but also enhance its bargaining power with payers, who favor less‑frequent dosing for cost‑containment. If MariTide secures regulatory approval and market uptake, Amgen could capture a meaningful share of the projected $200 billion U.S. obesity‑treatment market, reshaping its growth trajectory for the next decade.